Identifying novel targets for treatment of liver fibrosis: What can we learn from injured tissues which heal without a scar?

Current Drug Targets

Volumn 16, Issue 12, 2015, Pages 1332-1346

  Pritchard, Michele T ^a   McCracken, Jennifer M ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Extracellular matrix; Fibrosis; Hepatic stellate cell; Hyaluronan; Inflammation; Macrophage

Indexed keywords

CD14 ANTIGEN; CHEMOKINE RECEPTOR CCR2; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 10; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; PATTERN RECOGNITION RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ARTICLE; BACTEROIDETES; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; KUPFFER CELL; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; MACROPHAGE; MOLECULAR BIOLOGY; NONHUMAN; PRIMARY SCLEROSING CHOLANGITIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; WOUND HEALING; ANIMAL; DRUG EFFECTS; EXTRACELLULAR MATRIX; HEPATIC STELLATE CELL; IMMUNOLOGY; INJURIES; LIVER; LIVER CIRRHOSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; SKIN;

ANIMALS; EXTRACELLULAR MATRIX; HEPATIC STELLATE CELLS; HUMANS; LIVER; LIVER CIRRHOSIS; MACROPHAGES; SKIN; WOUND HEALING;

EID: 84946725758     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666150825111439     Document Type: Article

References (217)

1. [1] Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141(5): 1572-85.
2. [2] Bataller R, Rombouts K, Altamirano J, Marra F. Fibrosis in alcoholic and nonalcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 2011; 25(2): 231-44.
3. [3] Gunay-Aygun M. Liver and kidney disease in ciliopathies. Am J Med Genet C Semin Med Genet 2009; 151C(4): 296-306.
4. [4] Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M. Non alcoholic Fatty liver: epidemiology and natural history. Rev Recent Clin Trials 2014; 9(3): 126-33.
5. [5] Ismail MH, Pinzani M. Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies. Hepat Med 2011; 3: 69-80.
6. [6] Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest 2013; 123(5): 1887-901.
7. [7] Ceni E, Mello T, Galli A. Pathogenesis of alcoholic liver disease: Role of oxidative metabolism. World J Gastroenterol 2014; 20(47): 17756-72.
8. [8] Paik YH, Kim J, Aoyama T, De Minicis S, Bataller R, Brenner DA. Role of NADPH oxidases in liver fibrosis. Antioxid Redox Signal 2014; 20(17): 2854-72.
9. [9] Wells RG. The portal fibroblast: not just a poor man's stellate cell. Gastroenterology 2014; 147(1): 41-7.
10. [10] Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology 2014; 147(4): 765-83.
11. [11] Wick G, Grundtman C, Mayerl C, et al. The immunology of fibrosis. Annu Rev Immunol 2013; 31: 107-35.
12. [12] Ni HM, Williams JA, Yang H, Shi YH, Fan J, Ding WX. Targeting autophagy for the treatment of liver diseases. Pharmacol Res 2012; 66(6): 463-74.
13. [13] Eming SA, Krieg T, Davidson JM. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol 2007; 127(3): 514-25.
14. [14] Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest 2007; 117(5): 1219-22.
15. [15] Diegelmann RF, Evans MC. Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci 2004; 9: 283-9.
16. [16] Gao B, Jeong WI, Tian Z. Liver: An organ with predominant innate immunity. Hepatology 2008; 47(2): 729-36.
17. [17] Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. Immunity 2014; 41(1): 21-35.
18. [18] Freudenberg N, Schalk J, Galanos C, et al. Identification and percentage frequency of isolated non-parenchymal liver cells (NPLC) in the mouse. Virchows Arch B Cell Pathol Incl Mol Pathol 1989; 57(2): 109-15.
19. [19] Sleyster EC, Knook DL. Relation between localization and function of rat liver Kupffer cells. Lab Invest 1982; 47(5): 484-90.
20. [20] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34(5): 637-50.
21. [21] Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol 2014; 5: 461.
22. [22] Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41(3): 422-33.
23. [23] Bode C, Kugler V, Bode JC. Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J Hepatol 1987; 4(1): 8-14.
24. [24] Fukui H, Brauner B, Bode JC, Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol 1991; 12(2): 162-9.
25. [25] Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology 2006; 43(2 Suppl 1): S54-62.
26. [26] Knolle P, Schlaak J, Uhrig A, Kempf P, Meyer zum Buschenfelde KH, Gerken G. Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J Hepatol 1995; 22(2): 226-9.
27. [27] Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol 2009; 27: 147-63.
28. [28] Gao B, Seki E, Brenner DA, et al. Innate immunity in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2011; 300(4): G516-25.
29. [29] Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology 2014; 147(3): 577-94.
30. [30] Thurman RG. II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am J Physiol 1998; 275(4 Pt 1): G605-11.
31. [31] Nagy LE. Recent insights into the role of the innate immune system in the development of alcoholic liver disease. Exp Biol Med (Maywood) 2003; 228(8): 882-90.
32. [32] Dixon LJ, Barnes M, Tang H, Pritchard MT, Nagy LE. Kupffer cells in the liver. Compr Physiol 2013; 3(2): 785-97.
33. [33] Adachi Y, Bradford BU, Gao W, Bojes HK, Thurman RG. Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology 1994; 20(2): 453-60.
34. [34] Koop DR, Klopfenstein B, Iimuro Y, Thurman RG. Gadolinium chloride blocks alcohol-dependent liver toxicity in rats treated chronically with intragastric alcohol despite the induction of CYP2E1. Mol Pharmacol 1997; 51(6): 944-50.
35. [35] Fouts DE, Torralba M, Nelson KE, Brenner DA, Schnabl B. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol 2012; 56(6): 1283-92.
36. [36] Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005; 102(31): 11070-5.
37. [37] Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444(7122): 1022-3.
38. [38] Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature 2009; 457(7228): 480-4.
39. [39] Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and obesity. J Physiol 2009; 587(Pt 17): 4153-8.
40. [40] Yan AW, Fouts DE, Brandl J, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011; 53(1): 96-105.
41. [41] Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49(6): 1877-87.
42. [42] Chang CS, Chen GH, Lien HC, Yeh HZ. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1998; 28(5): 1187-90.
43. [43] Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48(2): 206-11.
44. [44] Gaeta GB, Perna P, Adinolfi LE, Utili R, Ruggiero G. Endotoxemia in a series of 104 patients with chronic liver diseases: prevalence and significance. Digestion 1982; 23(4): 239-44.
45. [45] Lin RS, Lee FY, Lee SD, et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 1995; 22(2): 165-72.
46. [46] Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev 2010; 90(3): 859-904.
47. [47] Inokuchi S, Tsukamoto H, Park E, Liu ZX, Brenner DA, Seki E. Toll-like receptor 4 mediates alcohol-induced steatohepatitis through bone marrow-derived and endogenous liver cells in mice. Alcohol Clin Exp Res 2011; 35(8): 1509-18.
48. [48] Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG. Tolllike receptor 4 is involved in the mechanism of early alcoholinduced liver injury in mice. Hepatology 2001; 34(1): 101-8.
49. [49] Yin M, Bradford BU, Wheeler MD, et al. Reduced early alcoholinduced liver injury in CD14-deficient mice. J Immunol 2001; 166(7): 4737-42.
50. [50] Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995; 108(1): 218-24.
51. [51] Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007; 47(4): 571-9.
52. [52] Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(23): 7381-91.
53. [53] Chassaing B, Etienne-Mesmin L, Gewirtz AT. Microbiota-liver axis in hepatic disease. Hepatology 2014; 59(1): 328-39.
54. [54] Cani PD, Delzenne NM. The gut microbiome as therapeutic target. Pharmacol Ther 2011; 130(2): 202-12.
55. [55] Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology 2015; 148(1): 30-6.
56. [56] Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57(2): 601-9.
57. [57] Rao RK, Seth A, Sheth P. Recent advances in alcoholic liver disease I. role of intestinal permeability and endotoxemia in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004; 286(6): G881-4.
58. [58] Wang Y, Kirpich I, Liu Y, et al. Lactobacillus rhamnosus GG treatment potentiates intestinal hypoxia-inducible factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury. Am J Pathol 2011; 179(6): 2866-75.
59. [59] Tabibian JH, O'Hara SP, Lindor KD. Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. Scand J Gastroenterol 2014; 49(8): 901-8.
60. [60] Ngu JH, Gearry RB, Wright AJ, Stedman CA. Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011; 9(12): 1092-7; quiz e135.
61. [61] Welcker K, Martin A, Kolle P, Siebeck M, Gross M. Increased intestinal permeability in patients with inflammatory bowel disease. Eur J Med Res 2004; 9(10): 456-60.
62. [62] Tabibian JH, Talwalkar JA, Lindor KD. Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res Int 2013; 2013: 389537.
63. [63] Kishore R, McMullen MR, Cocuzzi E, Nagy LE. Lipopolysaccharide- mediated signal transduction: Stabilization of TNF-alpha mRNA contributes to increased lipopolysaccharide-stimulated TNF-alpha production by Kupffer cells after chronic ethanol feeding. Comp Hepatol 2004; 3 Suppl 1: S31.
64. [64] McMullen MR, Pritchard MT, Wang Q, Millward CA, Croniger CM, Nagy LE. Early growth response-1 transcription factor is essential for ethanol-induced fatty liver injury in mice. Gastroenterology 2005; 128(7): 2066-76.
65. [65] Kishore R, Hill JR, McMullen MR, Frenkel J, Nagy LE. ERK1/2 and Egr-1 contribute to increased TNF-alpha production in rat Kupffer cells after chronic ethanol feeding. Am J Physiol Gastrointest Liver Physiol 2002; 282(1): G6-15.
66. [66] McMullen MR, Cocuzzi E, Hatzoglou M, Nagy LE. Chronic ethanol exposure increases the binding of HuR to the TNFalpha 3'- untranslated region in macrophages. J Biol Chem 2003; 278(40): 38333-41.
67. [67] Kishore R, McMullen MR, Nagy LE. Stabilization of tumor necrosis factor alpha mRNA by chronic ethanol: role of A + U-rich elements and p38 mitogen-activated protein kinase signaling pathway. J Biol Chem 2001; 276(45): 41930-7.
68. [68] Hritz I, Mandrekar P, Velayudham A, et al. The critical role of tolllike receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology 2008; 48(4): 1224-31.
69. [69] Zhao XJ, Dong Q, Bindas J, et al. TRIF and IRF-3 binding to the TNF promoter results in macrophage TNF dysregulation and steatosis induced by chronic ethanol. J Immunol 2008; 181(5): 3049-56.
70. [70] Petrasek J, Dolganiuc A, Csak T, et al. Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells. Hepatology 2011; 53(2): 649-60.
71. [71] Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002; 162(9): 1028-32.
72. [72] Agnese DM, Calvano JE, Hahm SJ, et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002; 186(10): 1522-5.
73. [73] Huang H, Shiffman ML, Friedman S, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007; 46(2): 297-306.
74. [74] Guo J, Loke J, Zheng F, et al. Functional linkage of cirrhosispredictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology 2009; 49(3): 960-8.
75. [75] Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology 2012; 143(5): 1158-72.
76. [76] Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
77. [77] Constandinou C, Henderson N, Iredale JP. Modeling liver fibrosis in rodents. Methods Mol Med 2005; 117: 237-50.
78. [78] Avasarala S, Yang L, Sun Y, et al. A temporal study on the histopathological, biochemical and molecular responses of CCl(4)- induced hepatotoxicity in Cyp2e1-null mice. Toxicology 2006; 228(2-3): 310-22.
79. [79] Wong FW, Chan WY, Lee SS. Resistance to carbon tetrachlorideinduced hepatotoxicity in mice which lack CYP2E1 expression. Toxicol Appl Pharmacol 1998; 153(1): 109-18.
80. [80] Gruebele A, Zawaski K, Kaplan D, Novak RF. Cytochrome P4502E1- and cytochrome P4502B1/2B2-catalyzed carbon tetrachloride metabolism: effects on signal transduction as demonstrated by altered immediate-early (c-Fos and c-Jun) gene expression and nuclear AP-1 and NF-kappa B transcription factor levels. Drug Metab Dispos 1996; 24(1): 15-22.
81. [81] Johansson I, Ingelman-Sundberg M. Carbon tetrachloride-induced lipid peroxidation dependent on an ethanol-inducible form of rabbit liver microsomal cytochrome P-450. FEBS Lett 1985; 183(2): 265-9.
82. [82] Luckey SW, Petersen DR. Activation of Kupffer cells during the course of carbon tetrachloride-induced liver injury and fibrosis in rats. Exp Mol Pathol 2001; 71(3): 226-40.
83. [83] Recknagel RO, Glende EA, Jr., Dolak JA, Waller RL. Mechanisms of carbon tetrachloride toxicity. Pharmacol Ther 1989; 43(1): 139-54.
84. [84] Rivera CA, Bradford BU, Hunt KJ, et al. Attenuation of CCl(4)- induced hepatic fibrosis by GdCl(3) treatment or dietary glycine. Am J Physiol Gastrointest Liver Physiol 2001; 281(1): G200-7.
85. [85] Nolan JP, Leibowitz AI. Endotoxin and the liver. III. Modification of acute carbon tetrachloride injury by polymyxin b--an antiendotoxin. Gastroenterology 1978; 75(3): 445-9.
86. [86] Rutenburg AM, Sonnenblick E, Koven I, Aprahamian HA, Reiner L, Fine J. The role of intestinal bacteria in the development of dietary cirrhosis in rats. J Exp Med 1957; 106(1): 1-14.
87. [87] Ingersoll MA, Spanbroek R, Lottaz C, et al. Comparison of gene expression profiles between human and mouse monocyte subsets. Blood 2010; 115(3): e10-9.
88. [88] Karlmark KR, Weiskirchen R, Zimmermann HW, et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 2009; 50(1): 261-74.
89. [89] Sica A, Invernizzi P, Mantovani A. Macrophage plasticity and polarization in liver homeostasis and pathology. Hepatology 2014; 59(5): 2034-42.
90. [90] Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 2014; 14(3): 181-94.
91. [91] Duffield JS, Forbes SJ, Constandinou CM, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005; 115(1): 56-65.
92. [92] Nagase H, Woessner JF, Jr. Matrix metalloproteinases. J Biol Chem 1999; 274(31): 21491-4.
93. [93] Duarte S, Baber J, Fujii T, Coito AJ. Matrix metalloproteinases in liver injury, repair and fibrosis. Matrix Biol 2015.
94. [94] Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G. Biochemical characterization of human collagenase-3. J Biol Chem 1996; 271(3): 1544-50.
95. [95] Fallowfield JA, Mizuno M, Kendall TJ, et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase- 13 and facilitate the resolution of murine hepatic fibrosis. J Immunol 2007; 178(8): 5288-95.
96. [96] Uchinami H, Seki E, Brenner DA, D'Armiento J. Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology 2006; 44(2): 420-9.
97. [97] Endo H, Niioka M, Sugioka Y, et al. Matrix metalloproteinase-13 promotes recovery from experimental liver cirrhosis in rats. Pathobiology 2011; 78(5): 239-52.
98. [98] Ramachandran P, Pellicoro A, Vernon MA, et al. Differential Ly- 6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci USA 2012; 109(46): E3186-95.
99. [99] Hironaka K, Sakaida I, Matsumura Y, Kaino S, Miyamoto K, Okita K. Enhanced interstitial collagenase (matrix metalloproteinase-13) production of Kupffer cell by gadolinium chloride prevents pig serum- induced rat liver fibrosis. Biochem Biophys Res Commun 2000; 267(1): 290-5.
100. [100] Ramachandran P, Iredale JP. Macrophages: central regulators of hepatic fibrogenesis and fibrosis resolution. J Hepatol 2012; 56(6): 1417-9.
101. [101] Elsharkawy AM, Oakley F, Mann DA. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 2005; 10(5): 927-39.
102. [102] Fischer R, Cariers A, Reinehr R, Haussinger D. Caspase 9- dependent killing of hepatic stellate cells by activated Kupffer cells. Gastroenterology 2002; 123(3): 845-61.
103. [103] Shan W, Palkar PS, Murray IA, et al. Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicol Sci 2008; 105(2): 418-28.
104. [104] Imamura M, Ogawa T, Sasaguri Y, Chayama K, Ueno H. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology 2005; 128(1): 138-46.
105. [105] Mitchell C, Couton D, Couty JP, et al. Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice. Am J Pathol 2009; 174(5): 1766-75.
106. [106] Baeck C, Wei X, Bartneck M, et al. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology 2014; 59(3): 1060-72.
107. [107] Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 1999; 259(2): 344-8.
108. [108] Muhlbauer M, Bosserhoff AK, Hartmann A, et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003; 125(4): 1085-93.
109. [109] Barnes MA, McMullen MR, Roychowdhury S, et al. Macrophage migration inhibitory factor is required for recruitment of scarassociated macrophages during liver fibrosis. J Leukoc Biol 2015; 97(1): 161-9.
110. [110] Heinrichs D, Knauel M, Offermanns C, et al. Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74. Proc Natl Acad Sci USA 2011; 108(42): 17444-9.
111. [111] Finucane OM, Reynolds CM, McGillicuddy FC, et al. Macrophage migration inhibitory factor deficiency ameliorates high-fat diet induced insulin resistance in mice with reduced adipose inflammation and hepatic steatosis. PLoS One 2014; 9(11): e113369.
112. [112] Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116(6): 1494-505.
113. [113] Akyildiz M, Gunsar F, Nart D, et al. Macrophage migration inhibitory factor expression and MIF gene -173 G/C polymorphism in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010; 22(2): 192-8.
114. [114] Assis DN, Leng L, Du X, et al. The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology 2014; 59(2): 580-91.
115. [115] Wang FF, Huang XF, Shen N, et al. A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still's disease. Arthritis Res Ther 2013; 15(3): R65.
116. [116] Dranoff JA, Wells RG. Portal fibroblasts: Underappreciated mediators of biliary fibrosis. Hepatology 2010; 51(4): 1438-44.
117. [117] Forbes SJ, Parola M. Liver fibrogenic cells. Best Pract Res Clin Gastroenterol 2011; 25(2): 207-17.
118. [118] Iwaisako K, Brenner DA, Kisseleva T. What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. J Gastroenterol Hepatol 2012; 27.Suppl 2 : 65-8.
119. [119] Blouin A, Bolender RP, Weibel ER. Distribution of organelles and membranes between hepatocytes and nonhepatocytes in the rat liver parenchyma. A stereological study. J Cell Biol 1977; 72(2): 441-55.
120. [120] Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88(1): 125-72.
121. [121] Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 2001; 21(3): 311-35.
122. [122] Blomhoff R, Green MH, Berg T, Norum KR. Transport and storage of vitamin A. Science 1990; 250(4979): 399-404.
123. [123] Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011; 25(2): 195-206.
124. [124] Wong L, Yamasaki G, Johnson RJ, Friedman SL. Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest 1994; 94(4): 1563-9.
125. [125] Pinzani M, Gesualdo L, Sabbah GM, Abboud HE. Effects of platelet- derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J Clin Invest 1989; 84(6): 1786-93.
126. [126] Friedman SL, Arthur MJ. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. J Clin Invest 1989; 84(6): 1780-5.
127. [127] Inagaki Y, Okazaki I. Emerging insights into transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 2007; 56(2): 284-92.
128. [128] Paradis V, Dargere D, Bonvoust F, Vidaud M, Segarini P, Bedossa P. Effects and regulation of connective tissue growth factor on hepatic stellate cells. Lab Invest 2002; 82(6): 767-74.
129. [129] Paradis V, Dargere D, Vidaud M, et al. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 1999; 30(4): 968-76.
130. [130] Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosisinducing ligand-dependent manners. Gastroenterology 2006; 130(2): 435-52.
131. [131] Krizhanovsky V, Yon M, Dickins RA, et al. Senescence of activated stellate cells limits liver fibrosis. Cell 2008; 134(4): 657-67.
132. [132] Troeger JS, Mederacke I, Gwak GY, et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology 2012; 143(4): 1073-83.
133. [133] Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGFbeta signaling and hepatic fibrosis. Nat Med 2007; 13(11): 1324-32.
134. [134] Brun P, Castagliuolo I, Pinzani M, Palu G, Martines D. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2005; 289(3): G571-8.
135. [135] Mazagova M, Wang L, Anfora AT, et al. Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. FASEB J 2015; 29(3): 1043-53.
136. [136] Seki E, Schwabe RF. Hepatic inflammation and fibrosis: Functional links and key pathways. Hepatology 2015; 61(3): 1066-79.
137. [137] Gressner OA, Rizk MS, Kovalenko E, Weiskirchen R, Gressner AM. Changing the pathogenetic roadmap of liver fibrosis? Where did it start; where will it go? J Gastroenterol Hepatol 2008; 23(7 Pt 1): 1024-35.
138. [138] Schultz GS, Wysocki A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen 2009; 17(2): 153-62.
139. [139] Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an information- rich system. Eur J Cell Biol 2006; 85(8): 699-715.
140. [140] Jiang D, Liang J, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiol Rev 2011; 91(1): 221-64.
141. [141] Taylor KR, Yamasaki K, Radek KA, et al. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem 2007; 282(25): 18265-75.
142. [142] Tran KT, Griffith L, Wells A. Extracellular matrix signaling through growth factor receptors during wound healing. Wound Repair Regen 2004; 12(3): 262-8.
143. [143] Duca L, Floquet N, Alix AJ, Haye B, Debelle L. Elastin as a matrikine. Crit Rev Oncol Hematol 2004; 49(3): 235-44.
144. [144] Maquart FX, Pasco S, Ramont L, Hornebeck W, Monboisse JC. An introduction to matrikines: extracellular matrix-derived peptides which regulate cell activity. Implication in tumor invasion. Crit Rev Oncol Hematol 2004; 49(3): 199-202.
145. [145] Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992; 267(36): 26031-7.
146. [146] Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003; 116(Pt 2): 217-24.
147. [147] Gaca MD, Zhou X, Issa R, Kiriella K, Iredale JP, Benyon RC. Basement membrane-like matrix inhibits proliferation and collagen synthesis by activated rat hepatic stellate cells: evidence for matrixdependent deactivation of stellate cells. Matrix Biol 2003; 22(3): 229-39.
148. [148] Sohara N, Znoyko I, Levy MT, Trojanowska M, Reuben A. Reversal of activation of human myofibroblast-like cells by culture on a basement membrane-like substrate. J Hepatol 2002; 37(2): 214-21.
149. [149] Friedman SL, Roll FJ, Boyles J, Arenson DM, Bissell DM. Maintenance of differentiated phenotype of cultured rat hepatic lipocytes by basement membrane matrix. J Biol Chem 1989; 264(18): 10756-62.
150. [150] Olsen AL, Bloomer SA, Chan EP, et al. Hepatic stellate cells require a stiff environment for myofibroblastic differentiation. Am J Physiol Gastrointest Liver Physiol 2011; 301(1): G110-8.
151. [151] Georges PC, Hui JJ, Gombos Z, et al. Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis. Am J Physiol Gastrointest Liver Physiol 2007; 293(6): G1147-54.
152. [152] Li Z, Dranoff JA, Chan EP, Uemura M, Sevigny J, Wells RG. Transforming growth factor-beta and substrate stiffness regulate portal fibroblast activation in culture. Hepatology 2007; 46(4): 1246-56.
153. [153] Perepelyuk M, Terajima M, Wang AY, et al. Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl oxidases in normal liver and early after injury. Am J Physiol Gastrointest Liver Physiol 2013; 304(6): G605-14.
154. [154] Schaffner F, Poper H. Capillarization of hepatic sinusoids in man. Gastroenterology 1963; 44: 239-42.
155. [155] Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol 2002; 1(1): 1.
156. [156] DeLeve LD, Wang X, Hu L, McCuskey MK, McCuskey RS. Rat liver sinusoidal endothelial cell phenotype is maintained by paracrine and autocrine regulation. Am J Physiol Gastrointest Liver Physiol 2004; 287(4): G757-63.
157. [157] Couvelard A, Scoazec JY, Feldmann G. Expression of cell-cell and cell-matrix adhesion proteins by sinusoidal endothelial cells in the nor mal and cirrhotic human liver. Am J Pathol 1993; 143(3): 738-52.
158. [158] Deleve LD, Wang X, Guo Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology 2008; 48(3): 920-30.
159. [159] Adzick NS, Longaker MT. Scarless fetal healing. Therapeutic implications. Ann Surg 1992; 215(1): 3-7.
160. [160] Brockes JP. Amphibian limb regeneration: rebuilding a complex structure. Science 1997; 276(5309): 81-7.
161. [161] Colwell AS, Longaker MT, Lorenz HP. Mammalian fetal organ regeneration. Adv Biochem Eng Biotechnol 2005; 93: 83-100.
162. [162] Glim JE, van Egmond M, Niessen FB, Everts V, Beelen RH. Detrimental dermal wound healing: what can we learn from the oral mucosa? Wound Repair Regen 2013; 21(5): 648-60.
163. [163] Namazi MR, Fallahzadeh MK, Schwartz RA. Strategies for prevention of scars: what can we learn from fetal skin? Int J Dermatol 2011; 50(1): 85-93.
164. [164] Larson BJ, Longaker MT, Lorenz HP. Scarless fetal wound healing: a basic science review. Plast Reconstr Surg 2010; 126(4): 1172-80.
165. [165] Cowin AJ, Brosnan MP, Holmes TM, Ferguson MW. Endogenous inflammatory response to dermal wound healing in the fetal and adult mouse. Dev Dyn 1998; 212(3): 385-93.
166. [166] Redd MJ, Cooper L, Wood W, Stramer B, Martin P. Wound healing and inflammation: embryos reveal the way to perfect repair. Philos Trans R Soc Lond B Biol Sci 2004; 359(1445): 777-84.
167. [167] Liu W, Cao Y, Longaker MT. Gene therapy of scarring: a lesson learned from fetal scarless wound healing. Yonsei Med J 2001; 42(6): 634-45.
168. [168] Frantz FW, Bettinger DA, Haynes JH, et al. Biology of fetal repair: the presence of bacteria in fetal wounds induces an adult-like healing response. J Pediatr Surg 1993; 28(3): 428-33.
169. [169] Rolfe KJ, Grobbelaar AO. A review of fetal scarless healing. ISRN Dermatol 2012; 2012: 698034.
170. [170] Liechty KW, Kim HB, Adzick NS, Crombleholme TM. Fetal wound repair results in scar formation in interleukin-10-deficient mice in a syngeneic murine model of scarless fetal wound repair. J Pediatr Surg 2000; 35(6): 866-72; discussion 72-3.
171. [171] Peranteau WH, Zhang L, Muvarak N, et al. IL-10 overexpression decreases inflammatory mediators and promotes regenerative healing in an adult model of scar formation. J Invest Dermatol 2008; 128(7): 1852-60.
172. [172] Canesso MC, Vieira AT, Castro TB, et al. Skin wound healing is accelerated and scarless in the absence of commensal microbiota. J Immunol 2014; 193(10): 5171-80.
173. [173] Cowin AJ, Holmes TM, Brosnan P, Ferguson MW. Expression of TGF-beta and its receptors in murine fetal and adult dermal wounds. Eur J Dermatol 2001; 11(5): 424-31.
174. [174] Shah M, Foreman DM, Ferguson MW. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995; 108 (Pt 3): 985-1002.
175. [175] Levine JH, Moses HL, Gold LI, Nanney LB. Spatial and temporal patterns of immunoreactive transforming growth factor beta 1, beta 2, and beta 3 during excisional wound repair. Am J Pathol 1993; 143(2): 368-80.
176. [176] Soo C, Beanes SR, Hu FY, et al. Ontogenetic transition in fetal wound transforming growth factor-beta regulation correlates with collagen organization. Am J Pathol 2003; 163(6): 2459-76.
177. [177] Hsu M, Peled ZM, Chin GS, Liu W, Longaker MT. Ontogeny of expression of transforming growth factor-beta 1 (TGF-beta 1), TGF-beta 3, and TGF-beta receptors I and II in fetal rat fibroblasts and skin. Plast Reconstr Surg 2001; 107(7): 1787-94; discussion 95-6.
178. [178] Eslami A, Gallant-Behm CL, Hart DA, et al. Expression of integrin alphavbeta6 and TGF-beta in scarless vs scar-forming wound healing. J Histochem Cytochem 2009; 57(6): 543-57.
179. [179] Olutoye OO, Yager DR, Cohen IK, Diegelmann RF. Lower cytokine release by fetal porcine platelets: a possible explanation for reduced inflammation after fetal wounding. J Pediatr Surg 1996; 31(1): 91-5.
180. [180] Haynes JH, Johnson DE, Mast BA, et al. Platelet-derived growth factor induces fetal wound fibrosis. J Pediatr Surg 1994; 29(11): 1405-8.
181. [181] Merkel JR, DiPaolo BR, Hallock GG, Rice DC. Type I and type III collagen content of healing wounds in fetal and adult rats. Proc Soc Exp Biol Med 1988; 187(4): 493-7.
182. [182] Cuttle L, Nataatmadja M, Fraser JF, Kempf M, Kimble RM, Hayes MT. Collagen in the scarless fetal skin wound: detection with picrosirius-polarization. Wound Repair Regen 2005; 13(2): 198-204.
183. [183] White ES, Baralle FE, Muro AF. New insights into form and function f fibronectin splice variants. J Pathol 2008; 216(1): 1-14.
184. [184] White ES, Muro AF. Fibronectin splice variants: understanding their multiple roles in health and disease using engineered mouse models. IUBMB Life 2011; 63(7): 538-46.
185. [185] Serini G, Bochaton-Piallat ML, Ropraz P, et al. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol 1998; 142(3): 873-81.
186. [186] Wong JW, Gallant-Behm C, Wiebe C, et al. Wound healing in oral mucosa results in reduced scar formation as compared with skin: evidence from the red Duroc pig model and humans. Wound Repair Regen 2009; 17(5): 717-29.
187. [187] Peled ZM, Phelps ED, Updike DL, et al. Matrix metalloproteinases and the ontogeny of scarless repair: the other side of the wound healing balance. Plast Reconstr Surg 2002; 110(3): 801-11.
188. [188] Dang CM, Beanes SR, Lee H, Zhang X, Soo C, Ting K. Scarless fetal wounds are associated with an increased matrix metalloproteinase- to-tissue-derived inhibitor of metalloproteinase ratio. Plast Reconstr Surg 2003; 111(7): 2273-85.
189. [189] Ulrich D, Ulrich F, Unglaub F, Piatkowski A, Pallua N. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with different types of scars and keloids. J Plast Reconstr Aesthet Surg 2010; 63(6): 1015-21.
190. [190] Simon F, Bergeron D, Larochelle S, et al. Enhanced secretion of TIMP-1 by human hypertrophic scar keratinocytes could contribute to fibrosis. Burns 2012; 38(3): 421-7.
191. [191] Huang EY, Wu H, Island ER, et al. Differential expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in early and late gestational mouse skin and skin wounds. Wound Repair Regen 2002; 10(6): 387-96.
192. [192] Lovvorn HN 3rd, Cheung DT, Nimni ME, Perelman N, Estes JM, Adzick NS. Relative distribution and crosslinking of collagen distinguish fetal from adult sheep wound repair. J Pediatr Surg 1999; 34(1): 218-23.
193. [193] Weissmann B, Meyer K, Sampson P, Linker A. Isolation of oligosaccharides enzymatically produced from hyaluronic acid. J Biol Chem 1954; 208(1): 417-29.
194. [194] Spicer AP, McDonald JA. Characterization and molecular evolution of a vertebrate hyaluronan synthase gene family. J Biol Chem 1998; 273(4): 1923-32.
195. [195] Itano N, Sawai T, Yoshida M, et al. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem 1999; 274(35): 25085-92.
196. [196] Jacobson A, Brinck J, Briskin MJ, Spicer AP, Heldin P. Expression of human hyaluronan synthases in response to external stimuli. Biochem J 2000; 348 Pt 1: 29-35.
197. [197] Yamada Y, Itano N, Hata K, Ueda M, Kimata K. Differential regulation by IL-1beta and EGF of expression of three different hyaluronan synthases in oral mucosal epithelial cells and fibroblasts and dermal fibroblasts: quantitative analysis using real-time RT-PCR. J Invest Dermatol 2004; 122(3): 631-9.
198. [198] McCracken, JM, Deshpande, KT and Pritchard MT. Liver injury and pro-fibrotic markers, but not frank fibrosis, are enhanced in Has3-/- mice after carbon tetrachloride exposure: potential role for enhanced matrix metabolism. Hepatol 2014; 60(1S):578A.
199. [199] Longaker MT, Chiu ES, Adzick NS, Stern M, Harrison MR, Stern R. Studies in fetal wound healing. V. A prolonged presence of hyaluronic acid characterizes fetal wound fluid. Ann Surg 1991; 213(4): 292-6.
200. [200] Sawai T, Usui N, Sando K, et al. Hyaluronic acid of wound fluid in adult and fetal rabbits. J Pediatr Surg 1997; 32(1): 41-3.
201. [201] King A, Balaji S, Le LD, Marsh E, Crombleholme TM, Keswani SG. Interleukin-10 regulates fetal extracellular matrix hyaluronan production. J Pediatr Surg 2013; 48(6): 1211-7.
202. [202] King A, Balaji S, Marsh E, et al. Interleukin-10 regulates the fetal hyaluronan-rich extracellular matrix via a STAT3-dependent mechanism. J Surg Res 2013; 184(1): 671-7.
203. [203] Longaker MT, Chiu ES, Harrison MR, et al. Studies in fetal wound healing. IV. Hyaluronic acid-stimulating activity distinguishes fetal wound fluid from adult wound fluid. Ann Surg 1989; 210(5): 667-72.
204. [204] Longaker MT, Harrison MR, Crombleholme TM, et al. Studies in fetal wound healing: I. A factor in fetal serum that stimulates deposition of hyaluronic acid. J Pediatr Surg 1989; 24(8): 789-92.
205. [205] Tolg C, McCarthy JB, Yazdani A, Turley EA. Hyaluronan and RHAMM in wound repair and the "cancerization" of stromal tissues. Biomed Res Int 2014; 2014: 103923.
206. [206] Leung A, Crombleholme TM, Keswani SG. Fetal wound healing: implications for minimal scar formation. Curr Opin Pediatr 2012; 24(3): 371-8.
207. [207] West DC, Shaw DM, Lorenz P, Adzick NS, Longaker MT. Fibrotic healing of adult and late gestation fetal wounds correlates with increased hyaluronidase activity and removal of hyaluronan. Int J Biochem Cell Biol 1997; 29(1): 201-10.
208. [208] Mast BA, Flood LC, Haynes JH, et al. Hyaluronic acid is a major component of the matrix of fetal rabbit skin and wounds: implications for healing by regeneration. Matrix 1991; 11(1): 63-8.
209. [209] Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol 2011; 26(5): 802-9.
210. [210] Vrochides D, Papanikolaou V, Pertoft H, Antoniades AA, Heldin P. Biosynthesis and degradation of hyaluronan by nonparenchymal liver cells during liver regeneration. Hepatology 1996; 23(6): 1650-5.
211. [211] Nakamura K, Yokohama S, Yoneda M, et al. High, but not low, molecular weight hyaluronan prevents T-cell-mediated liver injury by reducing proinflammatory cytokines in mice. J Gastroenterol 2004; 39(4): 346-54.
212. [212] Campo GM, Avenoso A, Campo S, D'Ascola A, Ferlazzo AM, Calatroni A. The antioxidant and antifibrogenic effects of the glycosaminoglycans hyaluronic acid and chondroitin-4-sulphate in a subchronic rat model of carbon tetrachloride-induced liver fibrogenesis. Chem Biol Interact 2004; 148(3): 125-38.
213. [213] Ohno S, Im HJ, Knudson CB, Knudson W. Hyaluronan oligosaccharides induce matrix metalloproteinase 13 via transcriptional activation of NFkappaB and p38 MAP kinase in articular chondrocytes. J Biol Chem 2006; 281(26): 17952-60.
214. [214] Fieber C, Baumann P, Vallon R, et al. Hyaluronan-oligosaccharideinduced transcription of metalloproteases. J Cell Sci 2004; 117(Pt 2): 359-67.
215. [215] Horton MR, Shapiro S, Bao C, Lowenstein CJ, Noble PW. Induction and regulation of macrophage metalloelastase by hyaluronan fragments in mouse macrophages. J Immunol 1999; 162(7): 4171-6.
216. [216] Higgins GM, Anderson RM. Experimental pathology of liver: Restoration of liver of the white rat following partial surgical removal. Arch Pathol 1931; 12: 186-202.
217. [217] Mehendale HM. Tissue repair: an important determinant of final outcome of toxicant-induced injury. Toxicol Pathol 2005; 33(1): 41-51.